

We “know” it works...so why doesn't it work?

The limits of screening and treatment for latent TB as a TB control strategy

Kevin Schwartzman MD, MPH
Respiratory Division, and
McGill International Tuberculosis Centre
McGill University
Montreal, Quebec, Canada

18th NAR--IUATLD Annual Conference
Boston, MA, USA
March 1, 2014

Disclosures

- I hold research grant funding from the Canadian Institutes of Health Research
- I work part-time for the Fonds de la Recherche du Québec—Santé [Quebec Health Research Funds]

Objectives

- To briefly review data illustrating the promise and limits of screening and treatment for latent tuberculosis infection (LTBI) as a TB control strategy
- To indicate potential reasons for its limited performance in this regard
- To highlight key areas for improvement

Comstock in Alaska




Fig 1.—Cumulative probability of developing active tuberculosis among persons with UNT during six years after start of controlled **trial**, by program year and medication prescribed.




Fig 3.—Cumulative probability of developing active tuberculosis among persons with UNT during six years after start of **demonstration project**, among persons for whom isoniazid was prescribed, by percent of annual dose taken.

- These studies involved isoniazid for one year, in Inuit communities
- In the RCT, one-third of subjects took >80% of doses, and half took 40-80%
- In the demonstration project, 80% of subjects took >40% of doses; average was 65%
- Comstock estimated that with similar adherence, and provision of treatment to all with “untreated non-active TB,” the incidence of active TB would fall by 30%

TB in Alaskan Inuit—A closer look

- The magnitude of the problem, and the impact of public health interventions, were unprecedented
- In 1949-51, the estimated annual risk of TB infection was 25%
- This fell to 1% by 1960
- The randomized trial of isoniazid began in winter 1957-58
- Treatment of LTBI could only have been a minor player

Flash forward...TBTC Study 26

Table 2. Number of Subjects with Tuberculosis and Event Rates.*

Population and Study Group	No. of Subjects	Subjects with Tuberculosis			Difference in Cumulative Rate†	Upper Limit of 95% CI for Difference in Cumulative Rate
		no.	<i>no. per patient-yr</i>	<i>cumulative rate</i>		
Modified intention-to-treat analysis						
Isoniazid only	3745	15	0.16	0.43	-0.24	0.01
Combination therapy	3986	7	0.07	0.19		
Per-protocol analysis						
Isoniazid only	2585	8	0.11	0.32	-0.19	0.06
Combination therapy	3273	4	0.05	0.13		

* Combination therapy consisted of 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg). Isoniazid-only therapy consisted of 9 months of self-administered daily isoniazid (300 mg). Data are shown for a period up to 33 months after study enrollment.

† The difference is the rate in the combination-therapy group minus the rate in the isoniazid-only group.

69% of eligible subjects assigned to 9INH completed it, versus 82% for 3HP

A great advance, but...

- Under **clinical trial conditions**, 69% of subjects completed the 9INH regimen (>240/270 doses)
- Results from the 3HP arm reflected directly observed treatment, which can have a very significant impact on TB control resources
 - Estimated incremental cost to health care system of \$21,500 per additional active TB case prevented, vs. 9INH—using data from the clinical trial
 - Shepardson et al, *IJTL* 2013
 - This refers to persons already in care
- The reality “on the ground” is quite different...

42 Studies, N=63,604 Immigrants		
	Percent	Number
Total number eligible for screening		1000
Proportion Completing Screening	77%	770
LTBI Prevalence	40%	308
Proportion Offered Treatment	76%	234
Proportion Started Treatment of Offered	88%	205
Proportion Completed Treatment of Started	59%	121
Program Effectiveness		
Proportion completed treatment of TST positive	121/400	30%
Proportion completed treatment of eligible for screening	121/1000	12%

Trung 1997, Adair 1999, Sutherland 1983, Parenti 1987, Lifson 2002, Varkey 2007, Sariaya 2002, Saiman 2001, Brassard, Minodier 2010, Levesque, 2004, Pottie 2007, Doering 1999, Scolari 1999, El-Hamad 2001, Carvalho 2005, Hurega 2002, Manzardo 2008, Garcia de Oalla 2003

Bettache et al, **Effectiveness of post-arrival LTBI screening programs in migrants**
[Slide courtesy of Dr. C. Greenaway; very similar findings for post-arrival surveillance programs]

Limited uptake and completion

- In North America, studies in other population groups e.g. contacts have shown similar or worse numbers
 - Health care workers often the worst—why?
- Note the substantial impact of non-attendance at screening, and of non-prescription by clinicians
 - Will direct observation and/or shorter regimens fix this?
 - Accuracy of diagnostic tools
 - Drug intolerance and toxicity
 - Limits of the hypertension analogy
 - No marker of successful LTBI treatment (≠ widespread BP cuffs)
 - Many treatment alternatives for hypertension
 - We have challenges even with symptomatic disease e.g. asthma

What about a totally different setting?

Table 2. Overall Effect of Community-wide Isoniazid Preventive Therapy: Tuberculosis Incidence and Prevalence.

Outcome	Control Clusters		Intervention Clusters		Rate Ratio (95% CI)*			
	Cases	Rate	Cases	Rate	Unadjusted	P Value	Adjusted†	P Value
	<i>no./no. of person-yr</i>	<i>per 100 person-yr‡</i>	<i>no./no. of person-yr</i>	<i>per 100 person-yr‡</i>				
Primary outcome: tuberculosis incidence§								
Any	856/29,014	2.95	887/29,352	3.02	1.00 (0.75–1.34)	0.98	0.96 (0.76–1.21)	0.71
Definite or probable	656/29,014	2.26	703/29,352	2.40	1.07 (0.70–1.64)	0.72	1.04 (0.73–1.48)	0.80


- Cluster-randomized trial involving nearly 79,000 South African gold miners in total
- ~14% prevalence of HIV infection, based on self-report so likely a marked underestimate
- Those in intervention clusters were offered TB screening and then 9 INH, in the absence of active TB disease
- Among miners who in fact took INH, there was a nearly 60% reduction in active TB during the 9-month treatment period, but this rapidly rebounded afterward

How efficient and cost-effective might mass screening and treatment be in the US?

TABLE 3. BASE CASE RESULTS OF AN ANALYSIS OF SCREENING FOR LTBI IN THE UNITED STATES

Risk-group	Number Needed to Screen	Incremental Cost-Effectiveness Ratio (\$/QALY)
Close-contact child		
No screen	—	—
Screen TST	110	6,200
Screen IGRA	104	21,100
Close-contact adult		
No screen	—	—
Screen TST	73	8,900
Screen IGRA	69	21,500
HIV-infected		
No screen	—	—
Screen TST	71	12,800
Screen IGRA	67	23,800
Recent immigrant adult		
No screen	—	—
Screen TST	136	Dominated
Screen IGRA	128	35,200
Foreign-born living in the US >5 yr age 6–14 yr		
No screen	—	—
Screen IGRA	358	52,900
Screen TST	380	Dominated
Foreign-born living in the US >5 yr age 25–44 yr		
No screen	—	—
Screen IGRA	301	57,400
Screen TST	319	Dominated
Foreign-born living in the US >5 yr age 15–24 yr		
No screen	—	—
Screen IGRA	424	63,200
Screen TST	450	Dominated

What kind of scale-up?



The bottom line (1)

- Treatment of LTBI is highly efficacious in clinical trial settings
- Real-world effectiveness is very different
 - 1950s-60s Alaska may have been a “best case” setting for impact of treatment, and many other factors were clearly at work
 - Current processes of screening and treatment leave many important gaps
- Impact of HIV, reinfection, drug resistance depending on setting

The bottom line (2)

- Huge logistical and cost challenges in North America and elsewhere, e.g. massive screening and treatment of foreign-born
 - Human resource needs
 - Could the necessary \$ be better spent?
- In the US and Canada, TB incidence is decreasing **without** broader-based LTBI treatment

What we need (1)

- Better diagnostics
 - Limits of TST and IGRAs well known
 - We need to be able to identify the small group most likely to yield both individual and population benefit from treatment of LTBI, so as to focus efforts
 - We need a marker for successful treatment
 - Targeted screening and treatment, for the 21st century

What we need (2)

- Better drug regimens
 - Much of the foregoing would become moot
- Better preventive tools e.g. vaccines
- Better engagement and mobilization
 - With our patients, their families and communities, providers, advocates and funders

- Thank you!